← Back to Search

Aerobic Exercise for Breast Cancer

Phase 2
Recruiting
Led By Jessica Scott, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female
Aged ≥18 years
Must not have
Contraindications to cardiopulmonary exercise testing including acute myocardial infarction within 3-5 days of any planned study procedures, unstable angina, uncontrolled arrhythmia causing symptoms or hemodynamic compromise, recurrent syncope, active endocarditis, acute myocarditis or pericarditis, symptomatic severe aortic stenosis, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures, thrombosis of lower extremities, suspected dissecting aneurysm, uncontrolled asthma, pulmonary edema, respiratory failure, acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis), room air desaturation at rest ≤ 85%
Mental impairment leading to inability to cooperate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks from baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two types of walking exercises: one with a fixed routine and one that changes based on how participants respond. The goal is to see which method better improves heart and lung fitness. Participants are people who can benefit from regular walking exercises.

Who is the study for?
This trial is for women over 18 with primary breast cancer, scheduled to receive chemotherapy, and currently exercising less than 90 minutes per week. They must be able to perform a baseline exercise test and agree to follow study procedures. It's not for those with other invasive cancers, severe heart or lung conditions, mental impairments affecting cooperation, or any illness that could interfere with the study.
What is being tested?
The study compares two types of Aerobic Training (AT) in breast cancer patients undergoing chemotherapy: Standard AT involves a fixed amount of walking each week; Adaptive AT adjusts exercise levels based on participants' responses. The effect on participants' cardiorespiratory fitness (CRF) will be evaluated.
What are the potential side effects?
While the trial focuses on aerobic training rather than medication side effects, potential risks may include typical exercise-related issues such as muscle soreness, fatigue, joint pain or injury. Participants' health will be closely monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am female.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with breast cancer and am scheduled for or receiving chemotherapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I don't have recent severe heart or lung issues that would stop me from safely doing exercise tests.
Select...
I am able to understand and follow study procedures.
Select...
My cancer has spread to distant parts of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks from baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks from baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardiorespiratory fitness (CRF) response rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Adaptive Aerobic Training/AT DosingExperimental Treatment1 Intervention
Participants with newly diagnosed primary breast cancer initiating chemotherapy.
Group II: Standard (fixed) Aerobic Training/AT dosingActive Control1 Intervention
Participants with newly diagnosed primary breast cancer initiating chemotherapy.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Surgery and radiation aim to remove or destroy cancer cells in the breast. Chemotherapy uses drugs to kill rapidly dividing cells, including cancer cells, throughout the body. Hormone therapy blocks hormones like estrogen that can promote cancer growth, while targeted therapy focuses on specific molecules involved in cancer cell growth and survival. Adaptive aerobic training, which adjusts exercise levels based on participants' responses, is important for breast cancer patients as it can improve cardiorespiratory fitness, reduce fatigue, and enhance overall quality of life during and after treatment.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,219 Total Patients Enrolled
206 Trials studying Breast Cancer
82,183 Patients Enrolled for Breast Cancer
Jessica Scott, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
700 Total Patients Enrolled
2 Trials studying Breast Cancer
318 Patients Enrolled for Breast Cancer

Media Library

Adaptive Aerobic Training/AT Dosing Clinical Trial Eligibility Overview. Trial Name: NCT05716893 — Phase 2
Breast Cancer Research Study Groups: Adaptive Aerobic Training/AT Dosing, Standard (fixed) Aerobic Training/AT dosing
Breast Cancer Clinical Trial 2023: Adaptive Aerobic Training/AT Dosing Highlights & Side Effects. Trial Name: NCT05716893 — Phase 2
Adaptive Aerobic Training/AT Dosing 2023 Treatment Timeline for Medical Study. Trial Name: NCT05716893 — Phase 2
~89 spots leftby Jan 2028